Vivimed Labs Hits Lower Circuit Amid Heavy Selling Pressure and Prolonged Downtrend

Stock Performance and Circuit Breaker Trigger

On 20 Jan 2026, Vivimed Labs (Stock ID: 612893) closed at ₹8.00, down ₹0.16 or 1.96% intraday, before hitting the lower circuit price band of ₹7.76. The stock’s price band was set at 5%, reflecting the maximum permissible daily price movement. The day’s trading saw a high of ₹8.16 and a low of ₹7.76, with total traded volume reaching approximately 4.76 lakh shares and turnover of ₹0.37 crore. This sharp decline capped a 19-day consecutive losing streak, during which the stock has plummeted by 67.64%, signalling sustained bearish momentum.

Heavy Selling Pressure and Market Context

The pharmaceutical and drugs sector, to which Vivimed Labs belongs, underperformed the broader market on the day. While the Sensex declined by 0.50% and the sector index fell by 0.76%, Vivimed Labs’ 1-day return was a steeper negative 1.72%, highlighting its relative weakness. The stock’s underperformance by 4.17% against its sector peers further emphasises the intense selling pressure it faced.

Investor participation has notably waned, with delivery volume on 19 Jan dropping to 32,450 shares, a staggering 94.85% decline compared to the 5-day average delivery volume. This sharp fall in delivery volume suggests a significant reduction in genuine investor interest, possibly due to panic selling and a lack of confidence in the stock’s near-term prospects.

Technical Indicators and Moving Averages

Technically, Vivimed Labs is trading below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — indicating a strong downtrend across multiple timeframes. Such positioning typically signals bearish sentiment and a lack of short-term buying support. The stock’s micro-cap market capitalisation of ₹67 crore further adds to its volatility and susceptibility to sharp price swings on relatively low volumes.

Fundamental and Market Sentiment Challenges

Vivimed Labs’ current Mojo Score stands at a low 24.0, with a Mojo Grade of Strong Sell as of 22 Dec 2025, reflecting deteriorated fundamentals and weak market outlook. This downgrade from a previously ungraded status signals heightened caution among analysts and investors alike. The company’s micro-cap status and limited liquidity, despite being sufficient for small trade sizes (₹0.02 crore based on 2% of 5-day average traded value), restrict its appeal to institutional investors, further exacerbating price volatility.

Persistent declines over nearly three weeks have likely triggered panic selling, as investors rush to exit positions amid fears of further losses. The unfilled supply of shares at lower price levels indicates a lack of buyers willing to absorb the selling pressure, which in turn pushes the stock towards its circuit limit. This dynamic often leads to sharp intraday falls and heightened volatility, as observed in Vivimed Labs’ trading session.

Implications for Investors and Market Participants

For investors, the stock’s current trajectory suggests caution. The sustained downtrend, combined with weak delivery volumes and a strong sell rating, points to limited near-term recovery prospects. Trading below all major moving averages and hitting new 52-week lows further reinforce the bearish technical outlook. Investors should carefully assess risk tolerance and consider alternative opportunities within the pharmaceutical sector or broader market.

Sector and Broader Market Context

The pharmaceutical sector has faced headwinds recently due to regulatory uncertainties, pricing pressures, and global supply chain disruptions. Vivimed Labs’ underperformance relative to its sector peers and the Sensex reflects these broader challenges. However, the stock’s micro-cap status and weak liquidity amplify its vulnerability to market swings, unlike larger, more diversified pharmaceutical companies that have shown resilience.

Investors looking to capitalise on sector opportunities may find better risk-adjusted returns in larger-cap pharmaceutical stocks with stronger fundamentals and more stable trading patterns. The current market environment favours companies with robust balance sheets, consistent earnings growth, and diversified product portfolios.

Outlook and Conclusion

Vivimed Labs’ recent plunge to its lower circuit limit and new 52-week low highlights the severity of selling pressure and negative sentiment surrounding the stock. The combination of a prolonged downtrend, weak investor participation, and a strong sell rating from MarketsMOJO underscores the challenges ahead. While the stock remains liquid enough for small trades, the lack of buying interest at current levels suggests further downside risk cannot be ruled out.

Investors should monitor key technical levels and fundamental developments closely. Until there is a clear reversal in trend or improvement in company fundamentals, caution remains the prudent approach. Diversifying into better-rated stocks within the pharmaceutical sector or other industries may offer more stable investment opportunities in the current market climate.

Unlock special upgrade rates for a limited period. Start Saving Now →